2002 Individual Investigator Grant Recipient – Andrew Godwin
Andrew Godwin, Ph.D.
Fox Chase Cancer Center
If and How Gleevec Might Work in Ovarian Cancer
The death rate from ovarian cancer is appallingly high. Most deaths occur because the tumor has spread from the ovary before detection of the disease. Thus, in order to cut death rates, either ovarian cancer must be detected earlier or treatments for metastatic ovarian tumors must improve. A drug known as Gleevec recently has been shown to be effective in treating patients with chronic myeloid leukemia and gastrointestinal stromal tumors. This drug inhibits a tyrosine kinase, an enzyme abnormally active in these cancers. Little is known about whether Gleevec might be effective against ovarian tumors. Dr. Godwin aims to evaluate the effects of this drug on ovarian cancer and identify the molecular pathways altered in response to this promising drug.
This award has been made possible by a generous grant from The Lee Kaplan Cancer Foundation Ltd. in memory of Lee Kaplan.